FDA Approves Temporary Heart Pump
Posted on: Tuesday, 7 October 2008, 15:15 CDT
The U.S. Food and Drug Administration said it has granted an exemption for the first heart pump that provides temporary support for the heart's right side.
The Humanitarian Device Exemption, or HDE, was granted to allow use of the pump that's designed to temporarily support certain critically ill patients.
The FDA said most heart assist devices support the heart's left ventricle, which pumps oxygen-rich blood to the rest of the body. The CentriMag Right Ventricular Assist System is intended for patients requiring support of their heart's right ventricle, which passes oxygen-depleted blood to the lungs to be refreshed with oxygen.
The federal agency said HDEs facilitate the development of medical devices intended to treat or diagnose a disease or condition affecting fewer than 4,000 people in the United States every year.
"This device will provide patients with much needed time until a more permanent treatment option is available," said Dr. Daniel Schultz, director of the FDA's Center for Devices and Radiological Health. "The approval reaffirms the FDA's commitment to even the smallest patient populations."
The CentriMag Right Ventricular Assist System is manufactured by Levitronix LLC of Waltham, Mass.
Source: United Press International
Related Articles
- Outcomes Registry in Heart Attack Patients to Generate Numerous Studies; Data Quality Ensured Through Velos Clinical Research Management System
- Study Data Show Positive European Experience With DuraHeart Left Ventricular Assist Device for Advanced Stage Heart Failure Patients
- New Data Demonstrates Value of Cardiac Devices and Diagnostics in Managing Heart Failure Patients
- Clinical Data Show CVRx(R) Rheos(R) Therapy Improved Heart Structure and Function in Early-Stage Heart Failure Patients
- Boston Scientific Launches Two Large-Scale Studies of Wireless Home Monitoring System for Heart Failure Patients
- FDA OKs drug for heart transplant patients
- Vanderbilt Enrolling Heart Failure Patients in New Pacing Device Study
- Data From Two Published Studies Show Short- and Long- Term Benefits of CHF Solutions' Aquapheresis(TM) Therapy in Treating Heart Failure Patients With Fluid Overload
- Role of Cholesterol Lowering Drugs in Heart Failure Patients Evaluated in Yale Medical Center's Heart Study
- Invasive Treatment May Be More Effective for Heart Attack Patients Presenting Late to Hospital
 |
 |
User Comments (0)
RSS Feeds